Nisa Investment Advisors
SYRS

Nisa Investment Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Nisa Investment Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-726
Closed -$14K – 2414
2021
Q4 		$14K Buy
+726
New +$29.4K ﹤0.01% 1988
2021
Q2 		– Sell
-1,300
Closed -$97 – 2396
2021
Q1 		$97 Hold
1,300
– – ﹤0.01% 1760
2020
Q4 		$141K Buy
+1,300
New +$119K ﹤0.01% 1604

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Nisa Investment Advisors's SYRS Position: Q1 2022 in Review

Nisa Investment Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2022, closing a stake of 726 shares — an estimated $14K sold.

Nisa Investment Advisors first reported a position in SYRS in Q4 2020 and held it in 3 quarters. The position peaked at $141K in Q4 2020. 94 funds tracked by Wall St. Rank hold SYRS as of Q1 2022.

  • Nisa Investment Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Nisa Investment Advisors sold 726 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $14K.
  • Nisa Investment Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Nisa Investment Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $141K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Nisa Investment Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.